Back A A A Font Size Receive E-mail Alerts Press Releases

Foreign Experts Visit MicroPort® During CIT 2018


Shanghai, China – Over a hundred experts from Asian Pacific and Latin American countries visited Shanghai MicroPort Medical Group Co., Ltd ("MicroPort®") during the CIT 2018 which was held in Suzhou, China, from March 22 to 25.
Jonathan Chen, Chief International Business Officer, extended a welcome speech to the experts while they visited the MicroPort® headquarters in Shanghai on March 21. Jonathan Chen made an introduction of the company development history, business sectors and blueprint, highlighting its global development strategy and international business development. The experts gained a deeper knowledge of the company's product portfolios and innovative technologies after visiting the Self-Experience exhibition center and the production lines.
On March 22, Dr. Costantino R. Costantini, Dr. Alfredo Rodriguez, Dr. Lee Kang-yin Michael, and Dr. Tam Li-wah received interviews from MicroPort®'s internal publication MicroPort® Review on the prospects of the coronary intervention and the challenges in this field. They highly recognized the contribution that MicroPort® had made in providing high-quality solutions to cardiovascular patients.
Dr. Costantini is a Brazilian expert in coronary intervention. Dr. Alfredo Rodriguez is an Argentine clinical researcher of Firebird2® and Waltz. He is also a member of Argentina Coronary Intervention Association. Dr. Lee Kang-yin Michael and Dr. Tam Li-wah are founder and President of HKSTENT respectively.
A dozen of Indian experts also visited the MicroPort® headquarters that day. They had in-depth discussion with the R&D personnel on product innovation and application.
The experts wrote down their wishes for MicroPort® after reviewing its 20 years of growth and development. Jonathan Chen thanked them for their supports. In the future, MicroPort® will continue to strive for innovation and provide platforms for clinicians and enterprises to strengthen mutual communication and cooperation to help develop more innovative products and technologies to benefit more patients.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to:

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 1998-2019 MicroPort Scientific Corporation

Leanne Li
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6953


[Prev]:MicroPort® Orthopedics Attends 2018 Qinling Joint Surgery Master Forum
[Next]:CIT 2018: MicroPort® Hosts Twilight Symposium "MicroPort® 20 Years – From Firehawk® to Firesorb®"